Developing RNA medicines to target cancer-driving cells in blood cancers
Blood cancers can arise from malignant stem and progenitor cells in the bone marrow. Treatments that address excess mature blood cells without eliminating these disease-starting cells leave the underlying cause untreated, creating a need for more targeted approaches.
Antigonie Biosciences is developing RNA medicines to silence cancer-driving mutations in bone marrow cells. Its Asteria delivery platform aims to eliminate malignant stem and progenitor cells; lead candidate W-0301 targets a mutation found in myeloproliferative neoplasms.
What stands out about Antigonie Biosciences
Reports in vivo activity and mutation-selective cell death in patient-derived samples for W-0301, its preclinical blood-cancer RNA medicine.
Won the pitching competition at Bionow's BioCap conference.
Selected for Phase II of Cancer Tech Accelerator and participated in PXN’s 2026 PraeSeed investor-readiness programme.
Spun out from Katherine Bridge's University of York laboratory in late 2025 to develop its LNP-RNA platform.
Founders Katherine Bridge and Cathy Hawley bring expertise in RNA-driven blood cancers and preclinical bone-marrow cell biology.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.